title: Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study.
abstract: Conjunctiva-associated lymphoid tissue (CALT) is closely associated with ocular surface immunity. This study investigated the effects of antiglaucoma prostaglandin analogs with or without benzalkonium chloride (BAK) preservative on organized CALT using an acute toxic model. A total of 48 albino rabbits were used and seven groups of treatments were constituted. Solutions (50 µl) of PBS, 0.02%BAK, (0.02%BAK+)latanoprost, (0.015%BAK+)travoprost, (0.005%BAK+)bimatoprost, (BAK-free)travoprost preserved with the SofZia® system or (BAK-free)tafluprost were instilled 15 times at 5-min intervals in both eyes. CALT changes were analyzed using in vivo confocal microscopy (IVCM), immunohistology in cryosections for detecting MUC-5AC+ mucocytes and CD45+ hematopoietic cells. Antiglaucoma eye drops stimulated inflammatory cell infiltration in the CALT, and seemed to be primarily related to the concentration of their BAK content. The CALT reaction after instillation of BAK-containing eye drops was characterized by inflammatory cell infiltration in the dome and intrafollicular layers and by cell circulation inside the lymph vessels. CD45 was strongly expressed in the CALT after instillation of all BAK-containing solutions at 4 h and decreased at 24 h. The number of MUC-5AC+ mucocytes around the CALT structure decreased dramatically after instillation of BAK-containing solutions. This study showed for the first time the in vivo aspect of rabbit CALT after toxic stimuli, confirming the concentration-dependent toxic effects of BAK. IVCM-CALT analysis could be a pertinent tool in the future for understanding the immunotoxicologic challenges in the ocular surface and would provide useful criteria for evaluating newly developed eye drops.
authors.affiliation: INSERM, U968, Paris, France.
authors.forename: Hong
authors.initials: H
authors.lastname: Liang
authors.forename: Christophe
authors.initials: C
authors.lastname: Baudouin
authors.forename: Antoine
authors.initials: A
authors.lastname: Labbe
authors.forename: Luisa
authors.initials: L
authors.lastname: Riancho
authors.forename: Françoise
authors.initials: F
authors.lastname: Brignole-Baudouin
mesh_terms: D000818:Animals; D001548:Benzalkonium Compounds / Q000009:adverse effects* / Q000494:pharmacology; D003228:Conjunctiva; D003231:Conjunctivitis / Q000139:chemically induced* / Q000378:metabolism* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005901:Glaucoma / Q000188:drug therapy*; D017493:Leukocyte Common Antigens / Q000378:metabolism; D008221:Lymphoid Tissue / Q000378:metabolism* / Q000473:pathology; D008297:Male; D055271:Mucin 5AC / Q000378:metabolism; D009883:Ophthalmic Solutions / Q000009:adverse effects* / Q000494:pharmacology; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects* / Q000494:pharmacology; D011453:Prostaglandins / Q000009:adverse effects* / Q000494:pharmacology; D011817:Rabbits
chemical_list: D001548:Benzalkonium Compounds; D055271:Mucin 5AC; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical; D011453:Prostaglandins; D017493:Leukocyte Common Antigens